SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Focused Visit (Follow-up) — Flannery O'Connor

PatientFlannery O'Connor
Date of birth2001-03-25
IdentifiersMRN HR-ML046-SYN; SSN (made up) 000-46-1853
Document date2026-07-27
AuthorAugusta Pemberton-Diallo, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Three-month review of lupus nephritis. [S]

History of Present Illness

Ms. O'Connor is thirteen weeks into treatment. Her joint pain and swelling settled within three weeks and the facial rash has faded with sun protection; she has had no fevers. She takes prednisone 10 mg a day, reached a month ago, mycophenolate 1000 mg twice daily (loose stools in the first two weeks, since settled), weekly belimumab by her own injection, hydroxychloroquine, and losartan. The rheumatology blood counts, weekly for the first month and twice monthly since, have stayed normal, with white cells between 4.8 and 7.9 and normal liver tests. The bladder infection in June grew Escherichia coli sensitive to nitrofurantoin and cleared after seven days. Her baseline eye examination a month ago was normal. She has gained 3.4 kg and sleeps less well on the days after a dose reduction. She writes five mornings a week. [S]

ElementDetail
Interval changeArthritis, rash, and fevers resolved; cystitis in June resolved
MedicinesPrednisone 10 mg; mycophenolate 2 g a day; belimumab weekly; hydroxychloroquine; losartan
MonitoringBlood counts and liver tests normal; eye examination normal
WorkWriting five mornings a week

Review of Systems

SystemResultFinding
ConstitutionalPositiveWeight up 3.4 kg; no fever
MusculoskeletalNegativeNo joint pain; no hip, groin, or knee pain
IntegumentaryNegativeRash gone; hair shedding less
GastrointestinalNegativeStools normal now
GenitourinaryNegativeNo urinary symptoms
PsychiatricPositivePoor sleep on some nights; mood good; PHQ-9 4

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Acetaminophen 500 mg oral tablet, two tablets (1000 mg) by mouth up to three times a day as needed for joint pain, no more than 3000 mg a dayTwo tablets up to every 8 hours as neededOral route2026-04-13activeS
Hydroxychloroquine sulfate 300 mg oral tablet, one tablet by mouth once daily (5 mg/kg of actual body weight), long termOne tablet once dailyOral route2026-04-22activeS
Losartan potassium 25 mg oral tablet, one tablet by mouth once daily, for proteinuria and blood pressureOne tablet once dailyOral route2026-04-22activeS
Methylprednisolone 500 mg intravenous infusion once daily for three daysOne infusion daily for three daysIntravenous route2026-04-29 to 2026-05-01completedS
Prednisone 5 mg oral tablet: 30 mg (six tablets) once daily from the day after the last pulse, reduced by 5 mg every two weeks to 10 mg, then to 5 mg a day or less by six monthsOnce daily, taperingOral route2026-04-29activeS
Mycophenolate mofetil 500 mg oral tablet, one tablet twice daily for one week, then two tablets (1000 mg) twice dailyTwo tablets twice dailyOral route2026-04-29activeS
Belimumab 200 mg/mL subcutaneous autoinjector: 400 mg (two injections) once weekly for four doses, then 200 mg once weeklyOnce weekly by self-injectionSubcutaneous route2026-04-29activeS
Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once dailyOne tablet once dailyOral route2026-04-29activeS
Nitrofurantoin (monohydrate/macrocrystals) 100 mg oral capsule, one capsule by mouth twice daily with food for seven daysOne capsule twice daily for seven daysOral route2026-06-15 to 2026-06-21completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-07-27Body height168cmS
2026-07-27Body weight63.4kgS
2026-07-27Body mass index (BMI) [Ratio]22.5kg/m2S
2026-07-27Systolic blood pressure122mm[Hg]S
2026-07-27Diastolic blood pressure78mm[Hg]S
2026-07-27Heart rate76/minS
2026-07-27Respiratory rate14/minS
2026-07-27Body temperature36.7CelS
2026-07-27Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-07-27Hemoglobin [Mass/volume] in Blood12.1g/dL12-15.5 g/dLNormalS
2026-07-27Leukocytes [#/volume] in Blood by Automated count5.210*3/uL4-11 10*3/uLNormalS
2026-07-27Lymphocytes [#/volume] in Blood by Automated count110*3/uL1-4.8 10*3/uLNormalS
2026-07-27Platelets [#/volume] in Blood by Automated count21210*3/uL150-400 10*3/uLNormalS
2026-07-27Creatinine [Mass/volume] in Serum or Plasma0.8mg/dL0.5-1.1 mg/dLNormalS
2026-07-27Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M101mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-07-27Potassium [Moles/volume] in Serum or Plasma4.4mmol/L3.5-5.1 mmol/LNormalS
2026-07-27Albumin [Mass/volume] in Serum or Plasma3.8g/dL3.5-5 g/dLNormalS
2026-07-27Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L<=33 U/LNormalS
2026-07-27Protein/Creatinine [Mass Ratio] in Urine0.9g/g<=0.2 g/gHighS
2026-07-27Erythrocytes [#/area] in Urine sediment by Microscopy high power field6/[HPF]<=2 /[HPF]HighS
2026-07-27DNA double strand Ab [Units/volume] in Serum72[IU]/mL<=29 [IU]/mLHighS
2026-07-27Complement C3 [Mass/volume] in Serum or Plasma84mg/dL90-180 mg/dLLowS
2026-07-27Complement C4 [Mass/volume] in Serum or Plasma13mg/dL10-40 mg/dLNormalS
2026-07-2725-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma36ng/mL30-100 ng/mLNormalS
2026-07-27Cholesterol [Mass/volume] in Serum or Plasma212mg/dL<=199 mg/dLHighS
2026-07-27Cholesterol in HDL [Mass/volume] in Serum or Plasma58mg/dL>=50 mg/dLNormalS
2026-07-27Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation128mg/dL<=99 mg/dLHighS
2026-07-27Triglyceride [Mass/volume] in Serum or Plasma130mg/dL<=149 mg/dLNormalS
2026-07-27Hemoglobin A1c/Hemoglobin.total in Blood5.3%<=5.6%NormalS
2026-07-27Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S
2026-07-27Pain severity - 0-10 verbal numeric rating [Score] - Reported1{score}S

Physical Exam

Vital signs recorded on 2026-07-27; see the Vital Signs section. [S]

SystemFinding
GeneralWell; slight fullness of the face
SkinNo malar rash; no mouth ulcers
MusculoskeletalNo synovitis; full, painless hip movement
CardiovascularNo edema

Problems

ProblemClinical statusVerificationCodeProvenance
Pain and swelling of the small joints of both hands, the wrists, and the knees for three months, with an hour of morning stiffness, evening fevers to 38 °C, fatigue, and a red rash over the cheeks and nose after sun; told elsewhere it might be rheumatoid arthritis; cause to be establishedresolvedconfirmed M25.50S — Synthetic presenting concern at the index visit, superseded by the diagnosis of systemic lupus erythematosus at the second visit; joint pain in 1950 with suspected rheumatoid arthritis is documented (D).
Protein and blood in the urine: protein-to-creatinine ratio 1.6 g/g and 18 red cells per high-power field, with normal creatinine; cause to be establishedresolvedconfirmed R80.9S — Synthetic presenting finding at the index visit, superseded by the kidney biopsy diagnosis at the third visit.
Systemic lupus erythematosus, classified by the EULAR/ACR criteria (ANA 1:640 homogeneous; score 32 before the biopsy): inflammatory arthritis, acute cutaneous lupus (malar rash), fever, leukopenia with lymphopenia, mild thrombocytopenia, low C3 and C4, anti-dsDNA and anti-Sm positive; antiphospholipid antibodies and lupus anticoagulant negativeactiveconfirmed M32.19S — Synthetic modern diagnosis and results; her systemic lupus erythematosus, diagnosed in Atlanta in late 1950 or early 1951, is documented (D), but no finding from her lifetime is used.
Lupus nephritis, ISN/RPS class III (A), focal proliferative, on kidney biopsy: endocapillary proliferation in 9 of 30 glomeruli, activity index 6 of 24, chronicity index 1 of 12, full-house immunofluorescence; no thrombotic microangiopathy; urine protein-to-creatinine ratio 1.8 g/g; normal kidney functionactiveconfirmed M32.14S — Synthetic biopsy result and class; kidney involvement is documented at the end of her life, but no kidney finding from her lifetime is used.
Long-term glucocorticoid treatment for lupus nephritis, tapering to 5 mg a day or lessactiveconfirmed Z79.52S — Synthetic treatment status; the documented steroid harm in her life is the reason the episode keeps glucocorticoids low.
Long-term mycophenolate mofetil, with belimumab, for lupus nephritis; bone and infection protection in placeactiveconfirmed Z79.624S — Synthetic treatment status.
Levonorgestrel intrauterine system for highly effective contraception during mycophenolate treatmentactiveconfirmed Z97.5S — Synthetic contraception, chosen by the patient.
Acute cystitis on mycophenolate, belimumab, and prednisone 15 mg: two days of burning, frequency, and urgency without fever or flank pain; urine culture grew Escherichia coli sensitive to nitrofurantoin; resolved with seven days of nitrofurantoinresolvedconfirmed N30.00S — Synthetic common infection in an immunosuppressed young woman; coded without hematuria because the persistent hematuria is from her nephritis.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryUrine protein-to-creatinine ratio and urine sedimentEvery 3 months during active treatmentCompleted today0.9 g/g, from 1.8; 6 red cells per high-power field
LaboratoryCreatinine, eGFR, and albuminEvery 3 months during active treatmentCompleted todayCreatinine 0.8, eGFR 101, albumin 3.8
LaboratoryAnti-dsDNA, C3, and C4Every 3 months during active treatmentCompleted todayAnti-dsDNA 72; C3 84; C4 13
LaboratoryBlood count and liver tests on mycophenolateWeekly for a month, twice monthly for two months, then monthlyCompleted todayWhite cells 5.2, lymphocytes 1.0, hemoglobin 12.1, platelets 212; ALT 22; earlier rheumatology counts normal
LaboratoryPotassium and creatinine after starting losartan2 to 4 weeks after startingDeferredMissed, a deviation from the protocol: the check due two to four weeks after losartan was started was not drawn, because the standing rheumatology orders were for blood counts only. The first potassium, at the sick visit seven and a half weeks after starting, was 4.6 with creatinine unchanged at 0.8, so no harm resulted. Corrective action: a basic metabolic panel was added to the standing orders at that visit, and any dose change will be followed by a check at two weeks
LaboratoryPotassiumWith each kidney panel on losartanCompleted today4.4 mmol/L
ExaminationBlood pressureEvery visitCompleted today122/78 mmHg, at target
LaboratoryGlucose and lipids on glucocorticoidsAt three monthsCompleted todayHbA1c 5.3 percent; total cholesterol 212, HDL 58, LDL 128, triglycerides 130
Laboratory25-hydroxyvitamin DAfter repletionCompleted today36 ng/mL
ExaminationAvascular necrosis symptomsEvery visitCompleted todayNo hip, groin, or knee pain
Medication safetyGlucocorticoid doseEvery visitCompleted todayPrednisone 10 mg; on schedule for 5 mg or less by six months
Medication safetyHydroxychloroquine baseline eye examinationWithin the first yearUp to dateA month ago: fundus, OCT, and visual fields normal
Medication safetyRecombinant zoster vaccine dose 21 to 2 months after dose 1Completed todayGiven today
Medication safetyContraception on mycophenolateEvery visitUp to dateIntrauterine system in place
SurveyMood on belimumab (PHQ-9)PeriodicallyCompleted todayPHQ-9 4
SurveyJoint pain scoreEvery visitCompleted today1 of 10
Self-managementSun protection and writing scheduleEvery visitCompleted todaySunscreen daily; writing five mornings a week

Goal progress:

Immunizations given today: Recombinant zoster vaccine, dose 2 of 2 [S]

Guideline basis: EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 2024;83(1):15-29 (2023); 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Arthritis Rheumatol 2025;77(9):1115-1135 (2024); 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol 2023;75(12):2088-2102 (2022); CELLCEPT (mycophenolate mofetil): prescribing information (blood count monitoring, embryofetal toxicity, contraception) (2026); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease and hypertension monographs (2026)

Follow-up: Prednisone to 7.5 mg next month. Rheumatology blood counts monthly. Preventive visit in October. Six-month review. Next scheduled visit 2026-10-05: adult preventive visit. [S]